SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Solvonis Therapeutics Says NIDA To Fund Early Preclinical Evaluation Of Svn-015
Brief: Solvonis Therapeutics Completes Corporate Restructuring Actions
Solvonis Therapeutic - Appoints global biopharma leader Paul Carter
Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes
Solvonis Therapeutic - Half-year Report
Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration
RCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile
Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results
Brief: Solvonis Therapeutics Initiates Studies For SVN-002 To Support 505(B)(2) Pathway And Advance Towards Phase 2B Trial
Solvonis Therapeutic - Translational Bridging Studies
Solvonis Therapeutic - Exercise of warrants
RCS - Solvonis Therapeutic - Solvonis Chair to speak at Lucid Capital Markets
Brief: Solvonis Therapeutics Announces £1 Mln Subscription To Accelerate AI Drug Discovery
Solvonis Therapeutic - £1m subscription to accelerate AI drug discovery
Solvonis Therapeutic - Holding(s) in Company
Solvonis Therapeutic - AGM Statement
Solvonis Therapeutic - Holding(s) in Company
RCS - Solvonis Therapeutic - Initiation of Research Coverage
Solvonis Therapeutic - Allowance of U.S. patent covering AI-supported CNS